Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
First received: November 4, 2003
Last updated: June 5, 2010
Last verified: October 2007

November 4, 2003
June 5, 2010
October 2004
December 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00072488 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
Whole-Body MRI in the Evaluation of Pediatric Malignancies

RATIONALE: New imaging procedures, such as whole-body MRI, may improve the ability to detect metastatic cancer and determine the extent of disease.

PURPOSE: This clinical trial is studying whole-body MRI to see how well it works compared to standard imaging procedures in detecting distant metastases in patients with solid tumors or lymphoma.



  • Compare non-inferior diagnostic performance of whole-body MRI (i.e., combination of turbo short-tau inversion-recovery (STIR) and out-of-phase imaging) vs conventional imaging (i.e., the combination of chest CT scan, scintigraphy [bone, gallium, meta-iodobenzylguanidine (MIBG), or optional fludeoxyglucose F 18 positron emission tomography (FDG-PET)] and abdominal/pelvic CT scan/MRI as indicated) for detecting distant metastases for use in staging common tumors in pediatric patients.


  • Determine the incremental benefit of adding out-of-phase T1-weighted gradient-recalled echo imaging to turbo STIR for detecting distant disease in these patients.
  • Determine, preliminarily, the relative accuracies of FDG-PET, whole-body MRI, and a combination of FDG-PET and whole-body MRI in detecting stage IV disease in these patients.
  • Determine the effects of multiple factors, including cancer type, site of primary tumor, and patient age, on diagnostic accuracy of whole-body MRI in these patients.
  • Determine the interobserver variability associated with interpreting whole-body MRI exams for detecting distant metastases in these patients.

OUTLINE: This is a multicenter study.

Patients undergo conventional MRI, CT scan, and/or scintigraphy (e.g., bone, meta-iodobenzylguanidine [MIBG], or gallium) and experimental whole-body MRI sequences. Patients may optionally undergo fludeoxyglucose F18 positron emission tomography (FDG-PET).

Patients with a lesion (or lesions) detected on whole-body MRI or FDG-PET at initial staging that are not confirmed by biopsy or other conventional imaging studies at staging repeat standard imaging at 3- to 6-month follow-up.

Patients with an abnormality that is considered highly suspicious for a metastasis or when biopsy proof of that metastasis is obtained receive treatment at the discretion of the treating physician.

Patients are followed annually for 3 years.

PROJECTED ACCRUAL: A total of 226 patients (45 with neuroblastoma, 54 with rhabdomyosarcoma, 27 with other sarcoma, and 100 with lymphoma) will be accrued for this study within 1 year.

Not Provided
Masking: Open Label
Primary Purpose: Diagnostic
  • Lymphoma
  • Neuroblastoma
  • Sarcoma
  • Procedure: computed tomography
  • Procedure: magnetic resonance imaging
  • Procedure: positron emission tomography
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
December 2005   (final data collection date for primary outcome measure)


  • Confirmed diagnosis OR newly diagnosed mass strongly suspected to represent 1 of the following:

    • Rhabdomyosarcoma
    • Ewing's sarcoma family of tumors
    • Neuroblastoma
    • Hodgkin's lymphoma
    • Non-Hodgkin's lymphoma
  • All imaging examinations (e.g., CT scan, MRI, or scintigraphy) must be performed within 14 days of each other and within 2 months of any diagnostic or operative procedure

    • Whole body MRI and positron emission tomography (PET) scanning (if PET scan is being done) must be done before treatment
    • Prior CT scan, conventional MRI, bone scintigraphy, gallium scintigraphy, or meta-iodobenzylguanidine (MIBG) scintigraphy performed at outside institutions allowed provided the same technical standards specified in this study were practiced
    • Bone scintigraphy required for patients with neuroblastoma, rhabdomyosarcoma, or other sarcomas
    • Gallium scintigraphy not required in lymphoma patients if PET scan is performed
  • No CNS primary tumor



  • 21 and under

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No active cardiac pacemakers


  • Not pregnant or nursing
  • No prior malignancy
  • No uncontrolled diabetes mellitus (for patients undergoing optional PET)

    • Patients with controlled diabetes mellitus must have a fasting blood glucose no greater than 200 mg/dL
  • No contraindications to MRI or CT scan (e.g., intracranial vascular clips)


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • Not specified


  • Prior biopsy or surgery allowed provided no more than 2 months has passed since the procedure
up to 21 Years
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
CDR0000339811, ACRIN-6660
Not Provided
Not Provided
American College of Radiology Imaging Network
National Cancer Institute (NCI)
Principal Investigator: Marilyn J. Siegel, MD Mallinckrodt Institute of Radiology at Washington University Medical Center
National Cancer Institute (NCI)
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP